Gujarat Kidney and Super Speciality Ltd

Gujarat Kidney and Super Speciality Ltd has announced the closure of its trading window effective July 1, 2026. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will reopen 48 hours after the declaration of the un-audited financial results for the quarter ending June 30, 2026. The date for the Board Meeting to consider these financial results will be communicated separately.

The Board of Directors of 544666, at its meeting on May 28, 2026, approved the audited standalone and consolidated financial results for the quarter/year ended March 31, 2026, with unmodified auditor's reports. The Board deferred the appointment of a CEO and decided to conduct a postal ballot for varying the objects of its IPO. Key appointments include Mr. Siddharth Atulbhai Shah as Internal Auditor for FY 2026-27 and SPANJ & Associates as Secretarial Auditor for five consecutive years from FY 2026-27 to FY 2030-31, subject to shareholder approval at the upcoming Annual General Meeting.

The company's Board of Directors, at its meeting on May 28, 2026, approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, confirming unmodified auditor reports. The Board deferred the appointment of a new CEO. Additionally, the company will conduct a postal ballot for shareholder approval to vary the objects of its IPO. Key appointments include Mr. Siddharth Atulbhai Shah as the Internal Auditor for FY 2026-27 and SPANJ & Associates as the Secretarial Auditor for five consecutive years (FY 2026-27 to 2030-31), subject to member approval. Mr. Shah is an Associate member of ICAI with 7 years of experience in assurance and internal audit. SPANJ & Associates is a firm with offices in Ahmedabad and Mumbai.

The Board of Directors of 544666, at its meeting on May 28, 2026, approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company confirmed that the auditor's reports on both standalone and consolidated financial results are unmodified. Additionally, the Board deferred the appointment of a CEO and announced a postal ballot for shareholder approval on varying IPO objects. Mr. Siddharth Atulbhai Shah was appointed as the Internal Auditor for FY 2026-27, and SPANJ & Associates were appointed as Secretarial Auditors for five consecutive years, subject to member approval.

The Board of Directors of 544666, at its meeting on May 28, 2026, approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company confirmed that the auditor's reports on both standalone and consolidated financial results are unmodified. Additionally, the Board deferred the appointment of a CEO and announced a postal ballot for shareholder approval regarding a variation in the objects of its IPO. The company also appointed Mr. Siddharth Atulbhai Shah as the Internal Auditor for FY 2026-27 and SPANJ & Associates as the Secretarial Auditor for five consecutive years, from 2026-27 to 2030-31, subject to member approval.

Gujarat Kidney and Super Speciality Ltd has scheduled a Board of Directors meeting on May 28, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The meeting will also address variation in objects of IPO, conduct a postal ballot, and appoint a Chief Executive Officer (CEO). The trading window has been closed from April 1, 2026, until 48 hours after the announcement of the audited financial results.

Gujarat Kidney and Super Speciality Ltd. released a monitoring agency report by Brickwork Ratings, detailing the utilization of funds raised through its IPO for the quarter ended March 31, 2026. The report, in compliance with SEBI regulations, confirms no deviation from the stated objectives of the IPO. The funds raised through the fresh issue of equity shares aggregated to ₹250.80 Crore.

Gujarat Kidney and Super Speciality Ltd (GKSL) is scaling up its renal care services by inducting 100 AI-powered haemodialysis machines across its network. The initial phase involves deploying 8 machines at Gujarat Multi Speciality Hospital, Godhra, within 10 days. These AI-enabled machines offer real-time data analysis for personalized patient treatment, early detection of complications, and improved consistency. The remaining units will be deployed in a phased manner, enhancing access to technology-enabled renal care across Gujarat.

Gujarat Kidney and Super Speciality Ltd's Board approved the incorporation of a Wholly Owned Subsidiary (WOS) on April 27, 2026, to expand healthcare services in Bharuch, Gujarat. This move, already approved by shareholders via postal ballot, aims to augment the company's existing medical facilities. The Board also appointed Ms. Vishakha Mahesh Phadke as Company Secretary and Compliance Officer and noted shareholder approvals for interim fund utilization for healthcare expansion, voluntary revision of financial statements, and the appointment of a secretarial auditor for FY2025-26.

Gujarat Kidney and Super Speciality Ltd has paid a total fine of ₹20,000 (including GST) to BSE Limited and National Stock Exchange of India Limited. The fine was imposed for failing to provide prior intimation about a Board of Directors meeting as required by Regulation 29 of SEBI (LODR) Regulations, 2015. The company confirmed the payment was made on April 16, 2026, within the prescribed timeline. The company stated that this levy has no impact on its financial, operational, or other activities.